All In Biotech

Drug Trial Radar · NCT02865005

Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study Comparing Dapsone 5% Gel (SEEGPharm SA) to Aczone® and Both Active Treatments Compared to Placebo (Vehicle) in the Treatment of Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: Dec 20, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,361 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,361

Actual

Start

Feb 2016

Primary completion

Nov 2016

Study completion Dec 2016

Sponsor

Lead sponsor
Seegpharm S.A.Industry
Sponsor type
Industry
First posted
Aug 12, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multi-center, double-blind, randomized, placebo-controlled trial of Dapsone 5.0% Gel in the treatment of acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

  • Dapsone 5.0% Gel (SEEGPharm)Drug

    Topical Gel

  • PlaceboOther

    Topical Gel

  • Dapsone 5.0% Gel (Allergan)Drug

    Topical Gel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparisons of Active Products: Mean percent change in the inflammatory lesion (papules and pustules) counts and non-inflammatory lesion (open and closed comedones) countsTime frame: Treatment Days: 84 days of dosing

Locations

36 sites in 2 countries. Site status is shown where the registry gives one.

  • Catawba Clinical Research

    Encino, California

  • Catawba Clinical Research

    Fullerton, California

  • Catawba Clinical Research

    La Mesa, California

  • Catawba Clinical Research

    Los Angeles, California

  • Catawba Clinical Research

    Los Angeles, California

  • Catawba Clinical Research

    Sherman Oaks, California

  • Catawba Clinical Research

    Temecula, California

  • Catawba Clinical Research

    Boca Raton, Florida

  • Catawba Clinical Research

    Brandon, Florida

  • Catawba Clinical Research

    Hialeah, Florida

  • Catawba Clinical Research

    Miami, Florida

  • Catawba Clinical Research

    Miramar, Florida

  • Catawba Clinical Research

    South Tampa, Florida

  • Catawba Clinical Research

    Tampa, Florida

  • Catawba Clinical Research

    Savannah, Georgia

  • Catawba Clinical Research

    New Orleans, Louisiana

  • Catawba Clinical Research

    Norfolk, Nebraska

  • Catawba Clinical Research

    Omaha, Nebraska

  • Catawba Clinical Research

    Las Vegas, Nevada

  • Catawba Clinical Research

    Las Vegas, Nevada

  • Catawba Clinical Research

    Las Vegas, Nevada

  • Catawba Clinical Research

    Endwell, New York

  • Catawba Clinical Research

    New York, New York

  • Catawba Clinical Research

    High Point, North Carolina

  • Catawba Clinical Research

    Wilmington, North Carolina

  • Catawba Clinical Research

    Cincinnati, Ohio

  • Catawba Clinical Research

    Jenkintown, Pennsylvania

  • Catawba Clinical Research

    Upper Saint Clair, Pennsylvania

  • Catawba Clinical Research

    Warminster, Pennsylvania

  • Catawba Clinical Research

    Nashville, Tennessee

  • Catawba Clinical Research

    Austin, Texas

  • Catawba Clinical Research

    El Paso, Texas

  • Catawba Clinical Research

    Mesquite, Texas

  • Catawba Clinical Research

    Norfolk, Virginia

  • Catawba Clinical Research

    Richland, Washington

  • Catawba Clinical Research

    Belize City, Belize

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.